Please check your internet connection and try again.
# TUSSO-QD
## Overview
Tusso-QD is a brand name for a combination product containing dextromethorphan and guaifenesin. Dextromethorphan is a cough suppressant, and guaifenesin is an expectorant.
## Primary Indications
* **Dextromethorphan:** Temporary relief of cough due to minor throat and bronchial irritation.
* **Guaifenesin:** Helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive.
## Adult Dosing
* **Dextromethorphan:** Typically 10-20 mg every 4 hours or 20-30 mg every 6-8 hours. Maximum daily dose is generally 120 mg.
* **Guaifenesin:** Typically 200-400 mg every 4 hours or 400-600 mg every 6-12 hours (extended-release formulations). Maximum daily dose is generally 2400 mg.
**Note:** Specific dosing for Tusso-QD will depend on the exact formulation and concentration of each ingredient. Always refer to the product labeling or local protocol.
## Pediatric Dosing
Dosing for children varies significantly by age and weight. It is crucial to consult the product labeling or a pediatrician for appropriate pediatric dosing. Dextromethorphan is generally not recommended for children under 6 years of age without medical supervision. Guaifenesin dosing is also age-dependent.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment for either component. However, caution should be exercised in patients with severe liver disease.
## Contraindications
* Hypersensitivity to dextromethorphan or guaifenesin.
* Use within 14 days of MAOI therapy (for dextromethorphan).
* Asthma, emphysema, chronic bronchitis, or persistent cough (use with caution, consult physician).
## Adverse Effects
* **Dextromethorphan:** Dizziness, drowsiness, nausea, vomiting, constipation. High doses can lead to euphoria, hallucinations, confusion, and respiratory depression.
* **Guaifenesin:** Dizziness, headache, nausea, rash, vomiting.
## Key Drug Interactions
* **Monoamine Oxidase Inhibitors (MAOIs):** Dextromethorphan can cause potentially life-threatening serotonin syndrome when used with MAOIs or within 14 days of MAOI discontinuation.
* **Serotonergic Drugs:** Increased risk of serotonin syndrome when combined with SSRIs, SNRIs, tricyclic antidepressants, triptans, tramadol, and other serotonergic agents.
* **CNS Depressants:** Additive CNS depression with alcohol, sedatives, hypnotics, benzodiazepines, and opioids.
## Monitoring
* Monitor for efficacy (cough suppression, improved mucus clearance).
* Monitor for adverse effects, particularly drowsiness, dizziness, and signs of serotonin syndrome.
## Clinical Pearls
* Tusso-QD is intended for symptomatic relief of cough and congestion. It does not treat the underlying cause of the cough.
* Ensure adequate hydration when using guaifenesin to promote effective mucus thinning.
* Patients should be advised to avoid driving or operating heavy machinery if experiencing drowsiness or dizziness.
* Combination products should be used cautiously in pediatric populations due to potential for overdose and difficulty in precise dosing.
***
**Disclaimer:** This information is intended for educational purposes for healthcare professionals and should not be considered a substitute for professional medical advice. Always consult the most current prescribing information, product labeling, and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations can vary based on individual patient factors and local protocols.
